HealthProves
Inicio/Fabricantes/Bryant Ranch Prepack
Perfil del fabricante

Bryant Ranch Prepack

Compañía farmacéutica88 productos registrados
88
productos registrados
4.705.846
notificaciones totales
788
retiradas registradas
68,5%
graves en total
Productos
mostrando 88 de 88
ProductoAprobadoNotificaciones ↓Señal principalRetiradas
1983393.086Insuficiencia cardíaca congestiva14
1953374.035Sinusitis2
2000359.779Falta de eficacia del fármaco para una indicación no aprobada25
2004267.198Síndrome de abstinencia10
1996243.012Diabetes mellitus tipo 265
—195.098Enfermedad renal crónica17
1997188.609Diabetes mellitus tipo 212
2007181.371Quemadura química de la piel4
1984153.758Gota7
1981133.343Bradicardia5
1995131.745rechazo del trasplante9
2002129.920síndrome serotoninérgico11
1993129.795síndrome serotoninérgico0
2002124.895síndrome serotoninérgico1
1982112.882Mieloma de células plasmáticas19
—99.522Asma1
198395.444Dificultad de aprendizaje22
199283.951Fibrilación auricular27
195470.807Problema económico7
199661.926Recaída de esclerosis múltiple4
199660.482Recaída de esclerosis múltiple4
199460.122Disminución de la glucosa en sangre14
—60.053Fibrilación auricular0
—55.871Dificultad de aprendizaje14
198149.201Suicidio consumado24
195547.736Mejora de condición preexistente47
201146.910Mutación viral identificada5
200144.739Mejora de condición preexistente46
201237.628Incontinencia urinaria0
198137.190Suicidio consumado0
197237.185Enfermedad renal crónica44
—34.483Mejora de condición preexistente12
198234.050Fibrilación auricular15
197233.218Enfermedad renal crónica11
200733.035Bradicardia7
199425.624Retención de líquidos6
198424.178Hipoglucemia4
197422.513Trastorno de la regulación de la temperatura100
199921.059cáncer de mama metastásico2
199920.653glioblastoma0
198919.859Lipodistrofia adquirida0
199119.328Dolor ocular17
196718.910Hipersensibilidad a fármaco14
199718.237Síndrome de piernas inquietas13
199216.314intoxicación accidental0
195215.902reacción paradójica al medicamento3
200415.305Aumento de triglicéridos en sangre3
—13.982Migraña0
200313.824Demencia7
—13.716Alergia alimentaria0
196413.177Enfermedad renal crónica0
198412.988Bebé con bajo peso al nacer20
197312.193Rubor17
199111.134Vasculitis4
197311.040Enfermedad renal terminal0
—10.538Migraña0
199410.007Fisuras cutáneas23
—8434aumento de la presión intraocular0
19957843Complicación neurológica de la anestesia3
—7700Mortinato1
19937469Amaurosis fugax4
19977285coma hipoglucémico2
20057280Insomnio inicial0
—7035Enfermedad renal crónica0
19936619Psoriasis6
19916351Enfermedad renal crónica3
19926276Perforación de úlcera duodenal2
—6066Edema periférico0
19855377Presencia de residuo del producto2
—5103Prolongación del complejo QRS del electrocardiograma2
19964791pérdida de sensibilidad0
19844229Amaurosis fugax0
20014152tic0
—4056Diabetes mellitus tipo 20
19413863Vasculitis pulmonar2
19953794coma hipoglucémico4
19593533Paro respiratorio4
—3478Lesión muscular6
19973404Hemograma completo anormal1
19843286Miodesopsias5
20013156Complicación de la sedación2
—2853Estreñimiento0
19732245Úlcera cutánea1
—2169vértigo0
20011632Complicación de la sedación0
19581575Anemia nefrogénica0
19791448Faringitis0
—784Estomatitis0
Historial de retiradas · 50 registradas
FechaClaseMotivoEmpresa
2 jun 2026IIIPresence of foreign substanceANI Pharmaceuticals, Inc.
29 may 2026IIFailed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.Golden State Medical Supply Inc.
27 may 2026IIFailed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.Lannett Company Inc.
29 abr 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
29 abr 2026IICGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limitZydus Pharmaceuticals (USA) Inc
9 abr 2026IIFailed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.The Harvard Drug Group LLC
20 mar 2026IICGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.Leading Pharma, LLC
10 ene 2026IIPresence of Foreign SubstanceGraviti Pharmaceuticals Private Limited
26 nov 2025IIIFailed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.SUN PHARMACEUTICAL INDUSTRIES INC
18 nov 2025IIICross Contamination with Other ProductsGlenmark Pharmaceuticals Inc., USA
20 oct 2025IIFailed Dissolution SpecificationsGolden State Medical Supply Inc.
10 oct 2025IIFailed Dissolution SpecificationsLannett Company Inc.
10 oct 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
10 oct 2025IIFailed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .The Harvard Drug Group LLC
19 sept 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
19 sept 2025IIFailed Dissolution SpecificationsAscend Laboratories, LLC
3 sept 2025IIFailed Impurities/Degradation SpecificationsGlenmark Pharmaceuticals Inc., USA
19 jun 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
19 jun 2025IIDefective container; blister packaging inadequately sealed.The Harvard Drug Group LLC
27 may 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
27 may 2025IICGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.Torrent Pharma Inc.
22 abr 2025IICGMP Deviations - products manufactured in a shared facility with Ezetimibe tablets.RemedyRePack Inc.
18 abr 2025IIcGMP DeviationsPreferred Pharmaceuticals, Inc.
24 mar 2025IICGMP DeviationsRemedyRepack Inc.
17 mar 2025IIFailed dissolution specifications: lower than specificationsBIOCON PHARMA INC
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
13 mar 2025IICGMP DeviationsGlenmark Pharmaceuticals Inc., USA
4 mar 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
4 mar 2025IIICross ContaminationSUN PHARMACEUTICAL INDUSTRIES INC
17 feb 2025IIDefective Delivery System: Leakage observed after oral solution was repackaged into unit-dose syringes.Safecor Health, LLC
27 dic 2024IIPresence of Particulate Matter: A market complaint was received of a glass piece in the vial.Eugia US LLC
17 dic 2024IIFailed Dissolution Specifications:Amerisource Health Services LLC
6 dic 2024IICGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.Aurobindo Pharma USA Inc
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
1 nov 2024IIcGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.Glenmark Pharmaceuticals Inc., USA
31 oct 2024IIDefective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).Noven Pharmaceuticals Inc
24 sept 2024IIPresence of Foreign Tablets/Capsules: A Carbamazepine Extended-Release 400 mg tablet was found in a 1000-count bottle of Atorvastatin Calcium Tablets, USP 40 mg.Nivagen Pharmaceuticals Inc
31 jul 2024IIPresence of Foreign Tablets; 3 fused tablets of Metformin ER 500 mg were found in bottle of Gabapentin TabletsGranules Pharmaceuticals Inc.
26 jul 2024IIPresence of Particulate Matter: Complaint received of a glass particle in the vial.Eugia US LLC

Clase I = probabilidad razonable de daño grave · Clase II = temporal o reversible · Clase III = improbable que cause daño.

Estado de registro

Algunos productos de Bryant Ranch Prepack no están registrados por la FDA para uso humano. Para las sustancias no registradas (péptidos, SARM sin registro humano) no existe ningún proveedor legítimo para uso humano. La ausencia de una vía de aprovisionamiento es la información de seguridad.